Asian Pacific Journal of Cancer Prevention

Asian Pacific Journal of Cancer Prevention (아시아태평양암예방학회)
권호 표지
DOI QR코드

DOI QR Code

Preclinical Activity of Lobaplatin as a Single Agent and in Combination with Taxanes for Ovarian Carcinoma Cells

  • Sun, Xu (The Clinical Department, Guizhou Yibai Pharmaceutical Co. Ltd.) ;
  • Lou, Li-Guang (Shanghai Institute of Materia Medica, Chinese Academy of Sciences) ;
  • Sui, Dong-Hu (The Clinical Department, Guizhou Yibai Pharmaceutical Co. Ltd.) ;
  • Wu, Xiao-Hua (The Department of Gynecologic Oncology, Fudan University Shanghai Cancer Center)
  • Published : 2014.12.18
Download PDF
⟨ Previous Next ⟩

Abstract

Lobaplatin, one of the third - generation platinum compounds, has shown encouraging anticancer activity in a variety of tumor types. However, the efficacy of lobaplatin in ovarian cancer has not been systemically evaluated. In this study, lobaplatin as a single agent and in combination with taxanes was investigated in - vitro and in an in vitro model of ovarian carcinoma. Using the sulforhodamine B (SRB) assay, the cytotoxic effects of lobaplatin alone and in combination with taxanes were compared with cisplatin and carboplatin in seven ovarian cancer cell lines. In addition, in - vitro antitumor activities were evaluated with cisplatin - sensitive and cisplatin - resistant human ovarian cancer xenografts in nude mice. The cytotoxicity of lobaplatin was similar to or higher than that of cisplatin and carboplatin, with $IC_{50}$ values from 0.9 to $13.8{\mu}mol/L$ in a variety of ovarian cancer cells. The combination of lobaplatin with docetaxel yielded enhanced cytotoxic activity in vitro. In addition, in platinum - sensitive ovarian cancer xenografts, lobaplatin alone showed similar antitumor activity to cisplatin and carboplatin. Furthermore, lobaplatin alone or in combination with docetaxel exhibited significant activity in platinum - resistant ovarian cancer xenografts. These results indicate that the use of lobaplatin alone or in combination with docetaxel might be a rational and novel therapeutic strategy for ovarian cancer. Further clinical development of lobaplatin is clearly warranted.

Keywords

References

  1. Alberts DS, Mason L (1989). Carboplatin in the treatment of ovarian cancer. Seminars Oncol, 16, 19-26.
  2. Chou TC, Talalay P (1984). Quantitative analysis of dose-effect relationships, the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul, 22, 27-55. https://doi.org/10.1016/0065-2571(84)90007-4
  3. Deng QQ, Huang XE, Ye LH, et al (2013). Phase II trial of $Loubo^{(R)}$ (Lobaplatin) and pemetrexed for patients with metastatic breast cancer not responding to anthracycline or taxanes. Asian Pac J Cancer Prev, 14, 413-7. https://doi.org/10.7314/APJCP.2013.14.1.413
  4. Engel JB, Martens T, Hahne JC, et al (2012). Effects of lobaplatin as a single agent and in combination with TRAIL on the growth of triple-negative p53-mutated breast cancers in vitro. Anti-Cancer Drugs, 23, 426-36. https://doi.org/10.1097/CAD.0b013e32834fb8ce
  5. Gietema JA, Guchelaar HJ, de Vries EG, et al (1993). A phase I study of lobaplatin (D-19466) administered by 72h continuous infusion. Anticancer Drugs, 4, 51-5. https://doi.org/10.1097/00001813-199302000-00007
  6. Gietema JA, De Vries EG, Sleijfer DT, et al (1993). A phase I study of 1, 2-diamminomethyl-cyclobutane-platinum (II)- lactate (D-19466; lobaplatin) admini-stered daily for 5 days. Br J Cancer, 67, 396-401. https://doi.org/10.1038/bjc.1993.73
  7. Gietema JA, Veldhuis GJ, Guchelaar HJ, et al (1995). Phase II and pharmacokinetic study of lobaplatin in patients with relapsed ovarian cancer. Br J Cancer, 71, 1302-7. https://doi.org/10.1038/bjc.1995.252
  8. Harstrick A, Bokemeyer C, Scharnofkse M, et al (1993). Preclinical activity of a new platinum analogue, lobaplatin, in cisplatinsensitive and-resistant human testicular, ovarian, and gastric carcinoma cell lines. Cancer Chemother Pharmacol, 33, 43-7. https://doi.org/10.1007/BF00686021
  9. Harstrick A, Casper J, Guba R, et al (1989). Comparison of the antitumor activity of cisplatin, carboplatin, and iproplatin against established human testicular cancer cell lines in vitro and in vitro. Cancer, 63, 1079-83. https://doi.org/10.1002/1097-0142(19890315)63:6<1079::AID-CNCR2820630607>3.0.CO;2-J
  10. Huang XE, Wei GL, Huo JG, et al (2013). Intrapleural or intraperitoneal lobaplatin for treatment of patients with malignant pleural effusion or ascites. Asian Pac J Cancer Prev, 14, 2611-4. https://doi.org/10.7314/APJCP.2013.14.4.2611
  11. Jakupec MA, Galanski M, Keppler BK (2003). Tumourinhibiting platinum complexes state of the art and future perspectives. Rev Physiol Biochem Pharmacol, 146, 1-54. https://doi.org/10.1007/s10254-002-0001-x
  12. Kim YH, Kim SC (2011). Recent advances in the biomarkers for epithelial ovarian cancer. J Gynecol Oncol, 22, 219-21. https://doi.org/10.3802/jgo.2011.22.4.219
  13. McKeage MJ (2001). Lobaplatin, a new antitumour platinum drug. Expert Opin Investig Drugs, 10, 119-28. https://doi.org/10.1517/13543784.10.1.119
  14. Oguri S, Sakakibara T, Mase H, et al (1988). Clinical pharmacokinetics of carboplatin. J Clin Pharmacol, 28, 208-15. https://doi.org/10.1002/j.1552-4604.1988.tb03134.x
  15. Ozols RF, Bundy BN, Greer BE, et al (2003). Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer, a Gynecologic Oncology Group study. J Clin Oncol, 21, 3194-200. https://doi.org/10.1200/JCO.2003.02.153
  16. Paine-Murrieta GD, Taylor CW, Curtis RA, et al (1997). Human tumor models in the severe combined immune deficient (scid) mouse. Cancer Chemother Pharmacol, 40, 209-14. https://doi.org/10.1007/s002800050648
  17. Peng S, Yang QX, Zhang T, et al (2014). Lobaplatin-TACE combined with radioactive 125I seed implantation for treatment of primary hepatocellular carcinoma. Asian Pac J Cancer Prev, 15, 5155-60. https://doi.org/10.7314/APJCP.2014.15.13.5155
  18. Skehan P, Storeng R, Scudiero D, et al (1990). New colorimetric cytotoxicity assay for anticancer-drug screening. J Natl Cancer Inst, 82, 1107-12. https://doi.org/10.1093/jnci/82.13.1107
  19. Suh DH, Kim K, Kim JW (2012). Major clinical research advances in gynecologic cancer in 2011. J Gynecol Oncol, 23, 53-64. https://doi.org/10.3802/jgo.2012.23.1.53
  20. Wang N, Lv YZ, Xu AH, et al (2014). Application of lobaplatin in trans-catheter arterial chemoembolization for primary hepatic carcinoma. Asian Pac J Cancer Prev, 15, 647-50. https://doi.org/10.7314/APJCP.2014.15.2.647
  21. Wu XY, Huang XE, Cao J, et al (2014). A predictive model for evaluating responsiveness to pemetrexed treatment in patients with advanced colorectal cancer. Asian Pac J Cancer Prev, 15, 5941-4. https://doi.org/10.7314/APJCP.2014.15.14.5941
  22. Xie C-Y, Xu Y-Pg, Jin W, Lou L-G (2012). Antitumor activity of lobaplatin alone or in combination with antitubulin agents in non-small-cell lung cancer. Anti-Cancer Drugs, 23, 698-705 https://doi.org/10.1097/CAD.0b013e328352cc10
  23. Voegeli R, SchumacherW, Engel J, et al (1990). D-19466, a new cyclobutane-platinum complex with antitumor activity. J Cancer Res Clin Oncol, 116, 439-42. https://doi.org/10.1007/BF01612990
  24. Zhao C, Wang XJ, Wang S, et al (2014). Lobaplatin combined floxuridine/pirarubicin-based transcatheter hepatic arterial chemoembolization for unresectable primary hepatocellular carcinoma. Asian Pac J Cancer Prev, 15, 2057-60. https://doi.org/10.7314/APJCP.2014.15.5.2057

Cited by

  1. Simultaneous quantitation of two diastereoisomers of lobaplatin in rat plasma by supercritical fluid chromatography with tandem mass spectrometry and its application to a pharmacokinetic study vol.38, pp.21, 2015, https://doi.org/10.1002/jssc.201500658
  2. An open-label, single-arm phase II clinical study of docetaxel plus lobaplatin for Chinese patients with pulmonary and hepatic metastasis of nasopharyngeal carcinoma vol.27, pp.7, 2016, https://doi.org/10.1097/CAD.0000000000000370
  3. Downregulation of SASH1 correlates with tumor progression and poor prognosis in ovarian carcinoma vol.11, pp.5, 2016, https://doi.org/10.3892/ol.2016.4345